Screener
Corvus Pharmaceuticals CRVS Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use asset | 751 | 839 |
| Investment in Angel Pharmaceuticals | 10,496 | 10,991 |
| Other assets | 1,720 | 855 |
| Total assets | $253,195 | $71,119 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,697 | $2,491 |
| Operating lease liability | 428 | 403 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's total assets?
- Corvus Pharmaceuticals (CRVS) reported total assets of $253.2M in Q1 2026.
- How has Corvus Pharmaceuticals's total assets changed year-over-year?
- Corvus Pharmaceuticals's total assets increased by 326.0% year-over-year, from $59.44M to $253.2M.
- What is the long-term trend for Corvus Pharmaceuticals's total assets?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total assets has grown at a -3.6% compound annual growth rate (CAGR), from $85.53M to $71.12M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Corvus Pharmaceuticals's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude